Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.

PHASE3CompletedINTERVENTIONAL
Enrollment

494

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions
Asthma
Interventions
DRUG

Foster 100/6mg NEXThaler

Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler

DRUG

Foster 100/6mg pMDI

Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA\_134a propellant

Trial Locations (52)

100000

Chiesi Clinical Trial site 15682, Beijing

100144

Chiesi Clinical Trial site 15672, Beijing

101100

Chiesi Clinical Trial site 15663, Beijing

132011

Chiesi Clinical Trial site 15676, Jilin

161002

Chiesi Clinical Trial site 15678, Qiqihar

200025

Chiesi Clinical Trial site 15630, Shanghai

200050

Chiesi Clinical Trial site 15664, Shanghai

201100

Chiesi Clinical Trial site 15654, Shanghai

213164

Chiesi Clinical Trial site 15643, Changzhou

300052

Chiesi Clinical Trial site 15642, Tianjin

300350

Chiesi Clinical Trial site 15634, Tianjin

330006

Chiesi clinical Trial site 15619, Nanchang

337055

Chiesi Clinical Trial site 15674, Pingxiang

408499

Chiesi Clinical Trial site 15680, Chongqing

421000

Chiesi Clinical Trial site 15675, Hengyang

430030

Chiesi Clinical Trial site 15614, Wuhan

450003

Chiesi Clinical Trial site 15679, Zhengzhou

453000

Chiesi Clinical Trial site 15681, Xinxiang

510120

Chiesi clinical Trial Site 15610, Guangzhou

511400

Chiesi Clinical Trial site 15610, Guangzhou

Chiesi Clinical Trial site 15668, Guangzhou

516001

Chiesi Clinical Trial site 15677, Huizhou

518052

Chiesi Clinical Trial site 15683, Shenzhen

524001

Chiesi Clinical Trial site 15607, Zhanjiang

570208

Chiesi Clinical Trial site 15673, Haikou

610041

Chiesi Clinical Trial site 15633, Chengdu

710061

Chiesi Clinical Trial site 15626, Xi'an

830054

Chiesi Clinical Trial site 15669, Ürümqi

5100150

Chiesi Clinical Trial site 15671, Guangzhou

Unknown

Chiesi Clinical Trial site 15641, Hefei

Chiesi Clinical Trial site 15662, Foshan

Chiesi clinical Trial site 15656, Guangzhou

Chiesi Clinical Trial site 15668, Guangzhou

Chiesi Clinical Trial site 15608, Shenzhen

Chiesi Clinical Trial site 15661, Wuhan

Chiesi clinical Trial site 15621, Shenyang

Chiesi clinical Trial site 15659, Hohhot

Chiesi Clinical Trial site 15630, Shanghai

Chiesi Clinical Trial site 15631, Shanghai

Chiesi Clinical Trial site 15665, Shanghai

Chiesi clinical Trial site 15636, Beijing

Chiesi Clinical Trial site 15638, Chongqing

Chiesi Clinical Trial site 15670, Guizhou

Chiesi clinical Trial Site 15611, Hebei

Chiesi Clinical trial site 15660, Jilin

Chiesi Clinical Trial site 15628, Shanghai

Chiesi clinical trial site 15637, Shanghai

Chiesi Clinical Trial site 15666, Shenzhen

Chiesi clinical Trial site 15633, Sichuan

010017

Chiesi Clinical Trial site 15650, Hohhot

030001

Chiesi Clinical Trial site 15625, Taiyuan

050000

Chiesi Clinical Trial site 15611, Shijiazhuang

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03453112 - Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. | Biotech Hunter | Biotech Hunter